The results suggest the potential application of UGT1A1 and the nine transporter proteins as biological markers for the evaluation of the ameliorative effect of LGZGD on NAFLD. This evidence concerns the gene UGT1A1 and metabolic dysfunction-associated steatotic liver disease.